MISOPROSTOL PFIZER TABLET Sør-Afrika - engelsk - South African Health Products Regulatory Authority (SAHPRA)

misoprostol pfizer tablet

pfizer laboratories (pty) ltd - tablet - see ingredients - each tablet contains misoprostol 200 ug

Pfizer (Australia) BUPIVACAINE HYDROCHLORIDE 0.5% (100mg/20mL) injection BP vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) bupivacaine hydrochloride 0.5% (100mg/20ml) injection bp vial

pfizer australia pty ltd - bupivacaine hydrochloride monohydrate, quantity: 105.4 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - bupivacaine injection is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery - field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in post operative pain or labour pain. - field block (minor nerve block amd infiltration). the choice of 2 strengths, 0.25% and 0.5%, makes it possible to vary the degree of motor blockade.

Pfizer (Australia) CYTARABINE 1g/10mL injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) cytarabine 1g/10ml injection vial

pfizer australia pty ltd - cytarabine, quantity: 1 g - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with

Pfizer (Australia) CYTARABINE 100mg/5mL injection vial Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer (australia) cytarabine 100mg/5ml injection vial

pfizer australia pty ltd - cytarabine, quantity: 100 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - primarily for induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blastphase) and erythroleukaemia. may be used alone or in combination with other antineoplastic agents, the best results often being obtained with combination therapy. children with non-hodgkin's lymphoma have benefited from a combination drug program (lsa 2l2) that includes cytarabine. indications as at 24 october 2001: cytarabine is indicated primarily for: induction and maintenance of remission in acute myelocytic leukaemia of both adults and children. it has also been found to be useful in the treatment of other leukaemias such as acute lymphocytic leukaemia, chronic myelocytic leukaemia (blast phase). cytarabine may be used alone or in combination with other antineoplastic agents, the best results are often obtained with combined therapy. children with